Obe-cel for severe lupus with kidney inflammation
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 65 years old
- You have been diagnosed with SLE (lupus) based on standard criteria
- You have active kidney disease (lupus nephritis) confirmed by a biopsy
- Your lupus is severe (SLEDAI-2K score of 8 or higher) and has not improved with prior treatments
- You have at least one lupus-related antibody (ANA, anti-dsDNA, or anti-Smith) in your blood
- You have not received any anti-CD19 therapy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called O-triple for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if it can control the disease and help protect kidney function.
This trial tests a medicine called obinutuzumab for people with lupus kidney disease (specifically class V membranous nephropathy) who have protein in their urine. The goal is to see if this treatment can reduce protein leakage and preserve kidney function.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.